Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF
Close

Hansa Biopharma AB (HNSA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
25.66 -0.22    -0.85%
03:27:00 - Real-time Data. Currency in SEK ( Disclaimer )
Type:  Equity
Market:  Sweden
ISIN:  SE0002148817 
S/N:  52671796
  • Volume: 4,678
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 25.46 - 26.00
Hansa Biopharma 25.66 -0.22 -0.85%

HNSA Balance Sheet

 
Featured here, the Balance Sheet for Hansa Biopharma AB, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
30/06
2023
31/03
2022
31/12
2022
30/09
Total Current Assets 1234.95 1393.42 1604.7 1319.33
Cash and Short Term Investments 1102.51 1286.82 1496.18 1215.28
Cash - - - -
Cash & Equivalents 1102.51 1286.82 1496.18 1215.28
Short Term Investments - - - -
Total Receivables, Net 129.94 105.57 67.18 103.1
Accounts Receivables - Trade, Net 70.56 47.22 42.96 52.48
Total Inventory 2.5 1.04 0.973 0.957
Prepaid Expenses - - 3.52 -
Other Current Assets, Total - - 36.85 -
Total Assets 1362.52 1499.69 1687.41 1381.01
Property/Plant/Equipment, Total - Net 31.63 33.92 35.84 35.01
Property/Plant/Equipment, Total - Gross - - 43.1 -
Accumulated Depreciation, Total - - -7.27 -
Goodwill, Net - - - -
Intangibles, Net 95.94 72.35 46.87 26.66
Long Term Investments - - - -
Note Receivable - Long Term 59.38 58.35 24.22 50.61
Other Long Term Assets, Total - - - -
Other Assets, Total -127.44 -104.53 -29.36 -102.14
Total Current Liabilities 301.59 240.9 264.71 205.44
Accounts Payable 57.27 61.12 62.48 49.1
Payable/Accrued - - - -
Accrued Expenses 145.22 95.81 100.32 89.08
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 7.26 7.21 7.16 7.08
Other Current liabilities, Total 91.84 76.77 94.75 60.17
Total Liabilities 1180.34 1085.02 1084.49 1036.19
Total Long Term Debt 858.59 817.2 783.93 783.93
Long Term Debt 840.91 797.68 762.6 760.79
Capital Lease Obligations 17.68 19.51 21.33 23.14
Deferred Income Tax 0.418 0.402 0.405 0.403
Minority Interest - - - -
Other Liabilities, Total -821.17 -771.16 -727.15 -714.38
Total Equity 182.18 414.67 602.91 344.82
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 182.18 414.67 55.03 344.82
Additional Paid-In Capital - - 3021.54 -
Retained Earnings (Accumulated Deficit) - - -2471.09 -
Treasury Stock - Common - - -2.59 -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total - - 0.014 -
Total Liabilities & Shareholders' Equity 1362.52 1499.69 1687.41 1381.01
Total Common Shares Outstanding - - - -
Total Preferred Shares Outstanding - - - -
* In Millions of SEK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HNSA Comments

Write your thoughts about Hansa Biopharma AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
BumHunters Archer
JohnJenga Sep 06, 2021 6:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1630923594_18712.jpg
Run baby
Peter Hovgaard
Peter Hovgaard Sep 03, 2020 2:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.redeye.se/research/792767/hansa-biopharma-plattformspotential-driver-upp-vardering?utm_source=avanza&utm_medium=RSS
Peter Hovgaard
Peter Hovgaard Aug 26, 2020 2:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://news.cision.com/hansa-biopharma-ab/r/the-eu-commission-grants-conditional-approval-for-idefirix-tm---imlifidase--in-highly-sensitized-kid,c3181977
Peter Hovgaard
Peter Hovgaard Aug 14, 2020 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://streamio.com/api/v1/videos/5f3512566f8d8dd4d8000001/public_show
Peter Hovgaard
Peter Hovgaard Aug 13, 2020 5:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://cdn.fbsbx.com/v/t59.2708-21/117831693_1914597025350073_1554897188658194790_n.pdf/Intron-Health-Research-Initiation-Hansa-Biopharma-A-Rare-Gem.pdf?_nc_cat=111&_nc_sid=0cab14&_nc_ohc=7LrlyVybJasAX84jF3U&_nc_ht=cdn.fbsbx.com&oh=3f8350d7915c58e168cbd3df20773c00&oe=5F36E9BE&dl=1
Capstar Go
Capstar Go Jun 25, 2020 5:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Press releases & NewsHansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU
Capstar Go
Capstar Go Jun 25, 2020 4:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CHMP recommendations approved
Harri Rautiainen
Harri Rautiainen Jun 11, 2018 5:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
152871054577145.jpg
Short-term dipping, in loger run a promising share.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email